Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia-Reference-Cited by-同舟云学术

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

Published:2004 Issue:12 Volume:100 Page:2592-2597
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Quintas-Cardama Alfonso,Kantarjian Hagop,O'Brien Susan,Garcia-Manero Guillermo,Rios Mary B.,Talpaz Moshe,Cortes Jorge

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference23 articles.

1. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

2. CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

3. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor

4. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia;International Journal of Hematology;2023-03-09

2. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option;Blood Reviews;2022-11

3. Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia;Hematologic Malignancies;2021

4. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2020-10

5. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.;Haematologica;2020-09-14